EUCTR2009-017376-25-DE进行中（未招募）不适用
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias - None
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Phase I component
- •1.Written informed consent provided.
- •2.18 years old or older.
- •3.Subjects must have relapsed/refractory leukemias for which no standard therapies are anticipated to result in a durable remission. Subjects with poor-risk myelodysplasia (MDS) [i.e. refractory anemia with excess blasts (RAEB-1 or RAEB-2) by WHO classification] and chronic myelomonocytic leukemia (CMML) are also eligible. Relapsed/refractory leukemias include acute non-lymphocytic leukemia (AML) by WHO classification, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), or chronic myelogenous leukemia (CML) in blast crisis. Subjects with agnogenic myeloid metaplasia (AMM) are also eligible.
- •4.Subjects ? 60 years of age with AML who are not candidates for or have refused standard chemotherapy.
- •5.Subject who have previously received an autologous stem cell transplant are allowed if a minimum of three months has elapsed from the time of transplant (T0) and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK1120212.
- •6.Subjects with a history of allogeneic stem cell transplant are eligible for study participation provided the following eligibility criteria are met:
- •transplant was > 100 days prior to study enrollment.
- •subject has not taken immunosuppressive medications for at least 1 month
- •no signs or symptoms of graft versus host disease other than Grade 1 skin involvement
- •no active infection
- •subject meets the remainder of the eligibility criteria outlined in this protocol
- •7.Eastern Cooperative Oncology Group (ECOG) performance status of ?2.
- •8.Life expectancy of at least four weeks.
- •9.Able to swallow and retain oral medication.
- •10.Male subjects must agree to use one of the contraception methods listed in Section 7.1 This criterion must be followed from the time of the first dose of study medication until four weeks after the last dose of study medication. However, the Sponsor advises that contraception be used for a total of 16 weeks following the last dose (based on the lifecycle of sperm).
- •11.A female subject is eligible to participate if she is of:
- •Non-childbearing potential
- •Child-bearing potential and agrees to use one of the contraception methods listed in Section 7.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until four weeks after the last dose of study medication.
- •Note: Oral contraceptives are not reliable due to potential drug-drug interaction.
- •12.CPP ? 4.0 mmol2/L2(50 mg2/dL2).
- •13.Adequate organ system function
- •Phase II component:
- •As for Phase I, except replace Criteria 2-4 with the following:
- •1.Histologically or cytologically confirmed diagnosis of relapsed or refractory acute myeloid leukemia (AML), poor-risk myelodysplasia (MDS) with greater than 5% blasts in marrow, or chronic myelomonocytic leukemia (CMML) with greater than 5% blasts in marrow. RAS status in the leukemic cells of bone marrow and peripheral blood must be determined prior to study entry for Cohort 1 and 3.
- •a.If a site has a RAS assay available which meets GSK approval, that site may use those results for study entry, but must have samples shipped prior to study entry for central testing.
- •2.For Cohort 1, subject must be 18 years old or greater and have a KRAS or NRAS mutation
排除标准
- •1. Hematological malignancy associated with human immunodeficiency virus (HIV) infection or solid organ transplant.
- •2. Concurrent malignancy of solid tumors. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled.
- •Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above.
- •3. Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization).
- •Note: For proliferative disease, hydroxyurea will be allowed during Week 1 and 2. See Section 8.1 for additional details.
- •4. Received corticosteroids or imatinib within 24 h of GSK1120212 administration.
- •5. Received gemtuzumab ozogamicin within two weeks of GSK1120212 adminstration.
- •6. Received an investigational anti-cancer drug within four weeks or 5 half-lives, whichever is shorter of GSK1120212 administration--as long as a minimum of 14 days has passed between the last dose of the prior investigational anti-cancer drug and the first dose of GSK1120212.
- •7. Received major surgery, radiotherapy, or immunotherapy within four weeks of GSK1120212 administration.
- •8. Received chemotherapy regimens with delayed toxicity within the last four weeks (six weeks for prior nitrosourea or mitomycin C). Received chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last two weeks.
- •9. Received a MEK inhibitor.
- •10. Current use of a prohibited medication or requires any of these medications during treatment with GSK1120212.
- •11. Current use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within seven days prior to the first dose of GSK1120212. Low dose (prophylactic) low molecular weight heparin is permitted provided that subject’s PT and PTT meet entry criteria. Subjects requireing therapeutic levels of LMWH must receive approval from GSK Medical Monitor and be monitored appropriately as clinically indicated.
- •12. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
- •13. History of retinal vein occlusion or central serous retinopathy, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, hypercholesterolemia, or history of hyperviscosity or hypercoagulability syndromes).
- •14. Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR
- •15. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- •16. Concurrent condition that in the investigator’s opinion would jeopardize compliance with the protocol.
- •17. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression.
- •Subjects previously treated for these conditions that have had stable central nervous system disease (verified with consecutive imaging studies) for >3 months, are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted.
- •Subjects are not permitted to receive enzyme inducing anti-e
研究者
相似试验
进行中（未招募）
1 期
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with CancerChildren and Adolescents with Cancers Harboring V600 mutationsMedDRA version: 17.1Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003596-35-FRGlaxoSmithKline Research & Development Ltd94
进行中（未招募）
1 期
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with CancerChildren and Adolescents with Cancers Harboring V600 mutationsMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003596-35-GBovartis Pharma Services AG145
进行中（未招募）
1 期
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory LeukemiasEUCTR2009-017376-25-BEGlaxoSmithKline Research & Development Ltd135
已完成
1 期
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)Primary MyelofibrosisACTRN12611000159954Gilead Sciences Inc.165
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002382-19-PLPDC*line Pharma SAS64